An open study to assess the safety and tolerability of meloxicam 15 mg in subjects with rheumatic disease and mild renal impairment

Revmatologiia

Volumn 35, Issue SUPPL. 1, 1996, Pages 56-60

  Bevis, P J R ^a   Bird, H A ^b   Lapham, G ^a  

^a BOEHRINGER INGELHEIM LTD   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Meloxicam; Non steroidal anti inflammatory drugs (NSAIDs); Renal function; Renal impairment; Rheumatic disease; Tolerability

Indexed keywords

CREATININE; MELOXICAM; N ACETYL BETA GLUCOSAMINIDASE; NONSTEROID ANTIINFLAMMATORY AGENT; POTASSIUM ION; UREA;

ABDOMINAL PAIN; ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE CLEARANCE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; HEADACHE; HUMAN; KIDNEY DISEASE; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RASH; RHEUMATIC DISEASE; UREA BLOOD LEVEL;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; DRUG TOLERANCE; FEMALE; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; OSTEOARTHRITIS; THIAZINES; THIAZOLES; TREATMENT OUTCOME;

EID: 0029932265     PISSN: 13100505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Engelhardt G, Homma D, Schlegel K, Utzmann R, Schnitzler Chr. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res 1995;44:423-33.
2. Huskisson EC, Ghozlan R, Kurthen R, Degner FL, Bluhmki E. A long term study to evaluate the safety and efficacy of meloxicam therapy in patients with rheumatoid arthritis. Br J Rheumatol 1996;35(suppl. 1):29-34.
3. Reginster JY, Distel M, Bluhmki E. A double-blind study to compare the efficacy and safety of meloxicam 7.5 mg and meloxicam 15 mg in patients with rheumatoid arthritis. Scand J Rheumatol 1994;Suppl 98:abstract no. 112.
4. Hosie J, Distel M, Bluhmki E. A six month trial comparing meloxicam 7.5 mg with diclofenac 100 mg SR in osteoarthritis. Rheumatol Eur 1995;24(suppl. 3):abstract no. E49.
5. Lemmel EM, Bolten W, Burgos-Vargas R et al. A double-blind placebo controlled study of 7.5 mg and 15 mg of meloxicam in patients with rheumatoid arthritis. Scand J Rheumatol 1994;Suppl 98:abstract no. 111.
6. Lund B, Distel M, Bluhmki E. A double-blind placebo controlled study of three different doses of meloxicam in patients with osteoarthritis (OA) of the knee. Scand J Rheumatol 1994;Suppl 98:abstract no. 117.
7. Wojtulewski JA, Schattenkirchner M, Barceló P et al. A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis. Br J Rheumatol 1996;35(suppl. 1):22-8.
8. Schmid J, Busch U, Heinzel G, Bozler G, Kaschke S, Kummer M. Meloxicam: pharmacokinetics and metabolic pattern after intravenous infusion and oral administration to healthy subjects. Drug Metab Disp 1995;23:1206-13.
9. Bird HA, Clarke AK, Fowler PD, Little S, Podgorski MR, Steiner J. An assessment of tenoxicam, a nonsteroidal antiinflammatory drug of long half-life, in patients with impaired renal function suffering from osteoarthritis or rheumatoid arthritis. Clin Rheumatol 1989;8:453-60.
10. Watson WA, Freer JP, Katz RS, Basch C. Kidney function during naproxen therapy in patients at risk for renal insufficiency. Semin Arthritis Rheum 1988;17(suppl. 2):12-6.
11. Whelton A, Stout RL, Spilman PS, Klassen DK. Renal effects of ibuprofen, piroxicam, and sulindac in patients with asymptomatic renal failure. Ann Intern Med 1990; 112:568-76.
12. Unsworth J, Sturman S, Lunec J, Blake DR. Renal impairment associated with non-steroidal anti-inflammatory drugs. Ann Rheum Dis 1987;46:233-6.
13. Mawer EG, Knowles BR, Lucas SB, Stirlanol RM, Tooth JA. Computer assisted prescribing of kanamycin for patients with renal insufficiency. Lancet 1972;i:12-5.
14. Ellis BG, Tucker SM, Thompson AE, Price RG. Presence of serum and tissue forms of N-acetyl-beta-glucosaminidase in urine from patients with renal disease. Clin Chim Acta 1975;64:195-202.
15. Dieppe PA, Doyle DV, Burry HC. Renal damage during treatment with antirheumatic drugs. Br Med J 1978;2:664.
16. Clive DM, Stoff JS. Renal syndromes associated with non-steroidal antiinflammatory drugs. N Engl J Med 1984;310:563-72.
17. Blackshear JL, Napier JS, Davidman M, Stillman MT. Renal complications of nonsteroidal antiinflammatory drugs: identification and monitoring of those at risk. Semin Arthritis Rheum 1985;14:163-75.
18. Henrich WL. Nephrotoxicity of nonsteroidal antiinflammatory agents. Am J Kidney Dis 1983;11:478-84.
19. Vane JR, Botting RM. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 1995; 44:1-10.
20. Anon. Relative safety of oral non-aspirin NSAIDS. Curr Probl Pharmacol 1994;20:9-12.
21. Xie W, Robertson DL, Simmons DL. Mitogen-inducible prostaglandins G/H synthase: a new target for non-steroidal antiinflammatory drugs. Drug Dev Res 1992;25: 249-65.
22. Appleton I, Tomlinson A, Willoughby DA. Inducible cyclooxygenase (COX-2): a safer therapeutic target? Br J Rheumatol 1994;33:410-2.
23. Engelhardt G, Bögel R, Schnitzler Chr, Utzmann R. Meloxicam: Influence on arachidonic acid metabolism. Part I. In vitro findings. Biochem Pharmacol 1996;51:21-8.
24. Engelhardt G, Bögel R, Schnitzler Chr, Utzmann R. Meloxicam: influence on arachidonic acid metabolism. Part II. In vivo findings. Biochem Pharmacol 1996;51: 29-38.